De Novo Letermovir for Cytomegalovirus Prophylaxis in Moderate-Risk Liver Transplant Recipients (ATC 2026) - Jun 17, 2026 - Abstract #Abstract B362; Pres time: Jun 21, 2026; 02:45 PM - 03:45 PM; Location: Exhibit Hall; "Though valganciclovir (VGC) remains the guideline-recommended standard-of-care agent for CMV prophylaxis after LT, letermovir (LTV) has shown to be a favorable alternative given reduced bone marrow toxicity. This study demonstrates that de novo LTV for CMV primary prophylaxis is safe and effective after moderate-risk LT. LTV prophylaxis is more likely to be completed than VGC and is associated with less myelosuppressive toxicity which allowed for higher doses of anti-metabolite immunosuppression and reduced healthcare resource utilization. Larger studies are needed to definitively evaluate the impact of LTV on rejection rates and transplant outcomes."
Clinical • CNS Disorders • Cytomegalovirus Infection • Hematological Disorders • Leukopenia • Neutropenia • Transplantation
|
|
H. Kleiboeker 1; J. Fose 2; C. Saddler 3; D. Al-Adra 3; J. Rice 3; M. Jorgenson 3
|